Followers | 145 |
Posts | 27567 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, June 19, 2009 11:06:02 AM
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
dwmoskowitz@genomed.com
Tel. 314.983.9938
ST. LOUIS—June 19, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it is launching a world-wide marketing campaign to increase its clients' lifespan by 10 years while rewarding its marketers with 10% of the patient revenues they bring in.
GenoMed published a series of papers in 2002-2004 showing that overactivity of angiotensin I-converting enzyme (ACE) was behind three-quarters of common diseases—heart disease, almost all cancers, autoimmune diseases, even some infectious diseases, etc. The company's CEO, David Moskowitz MD FACP, was able to reverse early stage kidney failure due to diabetes or high blood pressure, the two main causes of heart disease. It's quite likely that heart disease itself could be reversed. Thus, it is reasonable to estimate that proper inhibition of tissue ACE, if begun in time, could add a decade of life to patients.
GenoMed has published in the peer-reviewed medical literature a safe and effective way to inhibit tissue ACE. There is no medical or legal impediment to applying this method to any patient population on earth.
The problem has been to communicate these findings to the patients who need to know-- the world's 2 billion adults—at a time when public health no longer takes care of patients, and medicine has completely lost its nerve.
David W. Moskowitz, MD FACP, GenoMed's CEO and Chief Medical Officer, said "Education is key. There's no point finding the major aging gene for all vertebrates—which we believe ACE to be—and have our discovery still be a secret seven years later. We need help getting the word out. In a word, we need a global marketing campaign. We can't rely on public health officials, so we'll go to the grass roots."
Dr. Moskowitz continued, "We ask that people refer their friends and family who have high blood pressure, diabetes, or emphysema. We'll work with the patient for two months or so, at a cost of $75 per month ($7.50/month for poor people). That should get the patient on the right dose of the right ACE inhibitor and start them on the right path to live an extra 10 years."
Dr. Moskowitz ended by saying, "In return, we commit to paying our marketers 10% of what we earn as a result of their efforts. In the First World, people can expect to make an average of $15 per referral; in the Third World, $1.50. So you not only do right by your family and friends, you make a little money on the side. And who couldn't use a little extra money nowadays?"
About GenoMed
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™ in the world, GenoMed aims to arrest diabetes, hypertension, and emphysema everywhere on earth. Please contact Dr. Moskowitz if you have one of these diseases.
Recent GMED News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 09:16:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 08:48:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/10/2024 08:15:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/10/2024 04:11:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/08/2024 08:11:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/08/2024 07:59:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:21:08 PM
- Globus Medical Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/07/2024 08:15:00 PM
- Globus Medical Schedules First Quarter Earnings Release and Conference Call • GlobeNewswire Inc. • 04/16/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:07:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 11:50:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:35:42 PM
- Globus Medical Reports Fourth Quarter and Full Year 2023 Results • GlobeNewswire Inc. • 02/20/2024 09:15:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:08:54 PM
- Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call • GlobeNewswire Inc. • 02/13/2024 10:17:08 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 06:08:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:45:09 PM
- Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer • GlobeNewswire Inc. • 02/05/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:11:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:09:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:06:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:58:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:55:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:50:33 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM